Search Results for: car t

As candidates, almost all democrats have promised voters, in several elections, they will support parallel trade in pharmaceuticals from Canada and other high income countries. As elected officials, nothing happens. President Obama already has authority to permit imports of medicines, if he wanted to exercise it. But not only is the White House not fullfillinbg the promise to allow imports, it has promised the CEO of PhRMA and several big companies that they won’t allow parallel trade in the health reform bill.

Continue Reading →

The Center for American Progress hosted a video conference of Dr. Howard Dean talking about Health Care reform on Tueday. The video is on the web here. On this one hour program, Howard Dean spends a little over 3 minutes responding to allegations that he is a “shill” for BIO, on the issue of biosimilars.

Continue Reading →

The July 20, 2009 issue of BioCentury has an extensive report on the “Biosimilar fire Drill.” It discusses in detail the lobbying by the Biotechnology Industry Association (BIO, bio.org) to defeat efforts by President Obama, OMB, the FTC, Representative Waxman, Senator Brown, AARP, Public Citizen, PIRG, Consumers Union, KEI, Essential Action, and others, to reform the regulation to biologic medicines, so there is more generic competition. Continue Reading →

Note: Only a portion of the speech is reproduced here.

Hon’ble Co-Chairs/Madam Moderator, Distinguished Delegates,

Continue Reading →

*The author thanks Professor Marc Perlman (Brown University) for his comprehensive notes on the IGC deliberations.

Continue Reading →

Pope Benedict XVI today issued a statement saying that “On the part of rich countries, there is excessive zeal for protecting knowledge through an unduly rigid assertion of the right to intellectual property, especially in the field of health care.” The criticism came in a section of his most recent encyclical letter dealing with social issues, and specifically focusing on international human development and systemic failures of bodies large and small to solve development problems.

Continue Reading →

Today nine NGOs sent a letter the WHO Expert Working Group on R&D Financing. The letter focuses on issues about transparency, conflicts of interest, and EWG outcomes. The whole EWG seems to be going very badly right now, in part because of the US government and much of Northern Europe is working hand and glove with the pharmaceutical industry, and partly because the Gates Foundation is protecting big pharma and seems to have an ideological attachment to strong IPR.

Continue Reading →

The US Department of State “2009 Investment Climate Statement for Switzerland” provides an interesting and often unexpected portrait of the intellectual property landscape for a country that is often a hard-liner in global IPR negotiations. Continue Reading →